Caliper Life Sciences Licenses Monogram Biosciences' Microfluidics Patents
News May 03, 2007
The intellectual property licensed to Caliper originates from ACLARA BioSciences, which merged with Monogram in December of 2004. Financial terms of the agreement were not disclosed.
Through the agreement with Monogram, Caliper has created the microfluidics patent estate, further solidifying the company's Caliper Driven licensing program.
With the addition of the patents exclusively licensed from Monogram, the Caliper patent estate available for licensing under the Caliper Driven program now includes more than 335 United States patents.
"Microfluidics technology is gaining main-stream market adoption. It is a next-generation experimentation platform offering unprecedented data quality, workflow integration and scalability for critical research and diagnostic applications," said Kevin Hrusovsky, CEO of Caliper Life Sciences.
"By incorporating Monogram's microfluidic patent estate into our own, we are able to expand the overall breadth and versatility of the applications that we can now pursue - either on our own or with partners through our Caliper Driven program," Hrusovsky added.
"Caliper is the undisputed leader in developing the power of microfluidics," said Michael Dunn, chief business officer of Monogram Biosciences. "Given this leadership position, we see many advantages to combining our microfluidics intellectual property with Caliper's commercialization engine to further exploit the power of this innovative technology."
Microfluidic technology represents a revolution in laboratory experimentation, bringing the benefits of miniaturization, integration and automation to many research-based industries. Currently, 18 of the top 20 pharmaceutical companies, including AstraZeneca, Novartis and Vertex, along with a growing number of biotechnology and research institutions use Caliper's microfluidic-based LabChip® systems.
Caliper has also partnered with companies such as Affymetrix, Agilent Technologies, Bio-Rad Laboratories, Canon U.S. Life Sciences and Wako Pure Chemicals to further develop and commercialize LabChip-based solutions.
Under the terms of the license agreement, Monogram retains the right to practice the licensed microfluidics intellectual property for use with its proprietary eTag™ technology.
A research team developed a microfluidic-based drug screening chip that identifies synergistic interactions between two antibiotics in eight hours. This chip can be a cell-based drug screening platform for exploring critical pharmacological patterns of antibiotic interactions, along with potential applications in screening other cell-type agents and guidance for clinical therapies.READ MORE